In the present study, we measured the plasma levels of visfatin and NUCB2/nesfatin-1 in patients with COPD and in controls and investigated if these adipokines are associated with other markers of inflammation, lung function, the degree of emphysema, and symptoms or with the response to inhaled glucocorticoids in patients with COPD. This evidence concerns the gene NAMPT and pulmonary emphysema.